Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS);Servizo Galego de Saúde
发明人:
DE LA FUENTE FREIRE, María,LÓPEZ LÓPEZ, Rafael,ALONSO NOCELO, Marta,VÁZQUEZ RÍOS, Abi Judit
申请号：
AU2019206268
公开号：
AU2019206268A1
申请日:
2019.01.15
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
In the present invention, the use of the TAS1R3 receptor as a biomarker for application in cancer diagnosis, monitoring, and therapy is described for the first time. In this sense, the authors of the present invention have demonstrated that TAS1R3 is a biomarker of interest in oncology, useful for the diagnosis of the disease, and capable of providing relevant information thereupon, to monitor the evolution, select the treatment, and selectively direct therapeutic molecules. It has been determined that it is possible to identify therapies against this receptor, and that it is also possible to direct conjugates and controlled release systems of drugs, such as nanoparticles, observing a very effective intracellular accumulation thereof in primary, disseminated and metastatic tumor cells. On the other hand, the presence of TAS1R3 in circulating tumor cells (CTCs) has also been demonstrated. These are tumor cells released into the bloodstream by the primary tumor and are considered key factors in the creation of metastases, so that their detection in early stages will serve as an early detector of metastasis, and are also useful in monitoring the disease and evaluating of the response to drugs.
